Hikma Pharmaceuticals
↗London, United Kingdom
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and in-licensed pharmaceutical products. Founded in 1978 in Amman, Jordan, it has grown into a global leader with a significant presence in North America, the Middle East, North Africa (MENA), and Europe. The company operates through three primary segments: Injectables, Generics (Hikma Rx), and Branded pharmaceuticals.
Hikma is the third-largest supplier of generic injectable products by volume in the US and the second-largest pharmaceutical company in the MENA region. The company is known for its high-quality manufacturing standards, with 29 plants globally, many of which are FDA and EMA inspected. Hikma focuses on complex generics and specialty medicines, particularly in therapeutic areas such as oncology, respiratory, CNS, and anti-infectives.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generics and Specialty Pharmaceuticals
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.2B
Founded:1978
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Public Shareholders
STOCK
Exchange:LSE
Ticker:HIK
Market Cap:$6.01B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Injectables, Nasal Sprays, Inhalers, Oral Solids, Lyophilized products
Active Trials:15
Trial Phases:Phase 1: 2 | Phase 2: 3 | Phase 3: 5 | Phase 4: 5
FDA Approvals:180
EMA Approvals:12
CORPORATE STRUCTURE
Subsidiaries:Hikma Pharmaceuticals USA Inc., West-Ward Pharmaceuticals, Hikma Ventures, Xellia Pharmaceuticals (US FDF business)
Key Partnerships:Takeda (Brand licensing in MENA), Arecor Therapeutics (Co-development), Junshi Biosciences (Licensing for Toripalimab)
COMPETITION
Position:Leader
Competitors:Teva Pharmaceuticals, Sandoz, Viatris, Amneal Pharmaceuticals, Fresenius Kabi
LEADERSHIP
Key Executives:
Riad Mishlawi - CEO
Hafrun Fridriksdottir - President, Hikma Rx & Global R&D
Bill Larkins - President, Hikma Injectables
Scientific Founders:Samih Darwazah
Board Members:Said Darwazah (Executive Chairman), Mazun Darwazah (Executive Vice Chairman), Ali Al-Husry
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hikma Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.